摘要
目的观察促性腺素释放素类似物———曲普瑞林治疗特发性中枢性性早熟(ICPP)女孩的临床疗效。方法25例ICPP女孩用曲普瑞林治疗,起始治疗年龄为(8.6±0.7)a,治疗时间为12mo。观察治疗后性征和生长速率的改变,分析对骨龄的身高标准差分值(HtSDSBA)的增长以及预测成人终身高(PAH)的增长。结果治疗后乳房退缩,血清性激素水平降低,生长减速至青春期前水平,骨龄显著受抑。结论曲普瑞林能有效地抑制性征发育和骨龄增长,并改善预测成人身高。
AIM To observe the clinical effect of gonadotropin-releasing hormone analogues in the treatment of the girls with idiopathic central precocious puberty(ICPP). METHODS Twenty-five girls with ICPP treated with GnRH-A,initial age of treatment was (8.6±0.7) a,with therapentic duration 12 mo. Sexual characteristics,growth velocity and bone age(BA)were observed, height standard deviation score for BA (HtSDS BA) and predicted adult height(PAH) were analysed. RESULTS After treatment,the breasts and sexual hormone returned to prepubertal situation,growth velocity decreased to the prebutertal level,manuration of BA slowed significantly. CONCLUSION GnRH-A can effectively depress the sexual characteristics,reduce the maturation of BA,and also improve the PAH in girls with ICPP.
出处
《中国临床药学杂志》
CAS
2005年第3期146-148,共3页
Chinese Journal of Clinical Pharmacy
关键词
促性腺素释放素类似物
曲普瑞林
中枢性性早熟
骨龄年龄
gonadotropin-releasing hormone analogues
triptoreline
central precocious puberty
bone age
